
CTBO
Healthcare · Biotechnology · $563,600 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 17, 2019 | Time not confirmed | — | 19.63 | — |
| Dec 31, 2018 | Time not confirmed | — | 19.63 | — |
| Nov 13, 2018 | Time not confirmed | — | -0.01 | — |
| Jul 16, 2018 | Time not confirmed | — | -0.02 | — |
| Jun 30, 2018 | Time not confirmed | — | -44.02 | — |
| Feb 20, 2018 | Time not confirmed | — | -0.02 | — |
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in…